Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
14C-VX-407 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 14C-VX-407 | EXPERIMENTAL | Participants will receive a single oral dose of 14C-VX-407 after an overnight fast of at least 8 hours. |
| Name | Type | Description |
|---|---|---|
| 14C-VX-407 | DRUG | Solution for Oral Administration. |
Key Inclusion Criteria: * Body mass index (BMI) of 18.0 to 32.0 kilogram per meter square (kg/m\^2), inclusive * A total body weight of more than (\>) 50 kg * Participants must have regular bowel movements (i.e., average of more than or equal to (\>=) 1 and less than or equal to (\<=)3 stools per d...
14C-VX-407 is a carbon-14 labeled small molecule developed by Vertex Pharmaceuticals for autosomal dominant polycystic kidney disease (ADPKD). The radiolabel allows researchers to track how the compound is absorbed, distributed, metabolized, and excreted after a single oral dose. It is an investigational agent in Phase 1 testing.
14C-VX-407 is being studied in autosomal dominant polycystic kidney disease (ADPKD) as part of early clinical pharmacology work. The single recruiting trial enrolls healthy adult male volunteers rather than patients, and its purpose is to characterize the absorption, distribution, metabolism, and excretion of a single oral dose of the radiolabeled compound.
14C-VX-407 is developed by Vertex Pharmaceuticals Incorporated, which trades on Nasdaq under the ticker VRTX. Vertex is the sponsor of the Phase 1 metabolism and excretion study of the compound in autosomal dominant polycystic kidney disease.
14C-VX-407 is in Phase 1 clinical development. It is investigational and has not been approved for any use. One Phase 1 trial is currently recruiting, and no trials of 14C-VX-407 have been completed.
14C-VX-407 is being studied in one Phase 1 trial, NCT07868926, titled Absorption, Distribution, Metabolism, and Excretion of 14C-VX-407 After a Single Oral Dose. The trial is recruiting in the United States, plans to enroll 8 healthy male volunteers aged 19 years and older, and is an uncontrolled, non-randomized, open-label study.